266 related articles for article (PubMed ID: 28977114)
1. ADALIMUMAB FOR ULCERATIVE COLITIS: RESULTS OF A BRAZILIAN MULTICENTER OBSERVATIONAL STUDY.
Zacharias P; Damião AOMC; Moraes AC; Teixeira FV; Ludvig JC; Nones RB; Saad-Hossne R; Sassaki LY; Silva RPLD; Facchin L; Olandoski M; Kotze PG
Arq Gastroenterol; 2017 Dec; 54(4):321-327. PubMed ID: 28977114
[TBL] [Abstract][Full Text] [Related]
2. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.
Colombel JF; Sandborn WJ; Ghosh S; Wolf DC; Panaccione R; Feagan B; Reinisch W; Robinson AM; Lazar A; Kron M; Huang B; Skup M; Thakkar RB
Am J Gastroenterol; 2014 Nov; 109(11):1771-80. PubMed ID: 25155227
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; van Assche G; Reinisch W; Colombel JF; D'Haens G; Wolf DC; Kron M; Tighe MB; Lazar A; Thakkar RB
Gastroenterology; 2012 Feb; 142(2):257-65.e1-3. PubMed ID: 22062358
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab for maintenance therapy for one year in Crohn's disease: results of a Latin American single-center observational study.
Kotze PG; Abou-Rejaile VR; Uiema LA; Olandoski M; Sartor MC; Miranda EF; Kotze LM; Saad-Hossne R
Arq Gastroenterol; 2014; 51(1):39-45. PubMed ID: 24760063
[TBL] [Abstract][Full Text] [Related]
5. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Sands BE; Peyrin-Biroulet L; Loftus EV; Danese S; Colombel JF; Törüner M; Jonaitis L; Abhyankar B; Chen J; Rogers R; Lirio RA; Bornstein JD; Schreiber S;
N Engl J Med; 2019 Sep; 381(13):1215-1226. PubMed ID: 31553834
[TBL] [Abstract][Full Text] [Related]
6. [Long-term adalimumab therapy in ulcerative colitis in clinical practice: result of the Hungarian multicenter prospective study].
Rutka M; Bálint A; Farkas K; Palatka K; Lakner L; Miheller P; Rácz I; Hegede G; Vincze Á; Horváth G; Szabó A; Nagy F; Szepes Z; Gábor Z; Zsigmond F; Zsóri Á; Juhász M; Csontos Á; Szűcs M; Bor R; Milassin Á; Molnár T
Orv Hetil; 2016 May; 157(18):706-11. PubMed ID: 27106726
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab in active ulcerative colitis: a "real-life" observational study.
; Armuzzi A; Biancone L; Daperno M; Coli A; Pugliese D; Annese V; Aratari A; Ardizzone S; Balestrieri P; Bossa F; Cappello M; Castiglione F; Cicala M; Danese S; D'Incà R; Dulbecco P; Feliciangeli G; Fries W; Genise S; Gionchetti P; Gozzi S; Kohn A; Lorenzetti R; Milla M; Onali S; Orlando A; Papparella LG; Renna S; Ricci C; Rizzello F; Sostegni R; Guidi L; Papi C
Dig Liver Dis; 2013 Sep; 45(9):738-43. PubMed ID: 23683530
[TBL] [Abstract][Full Text] [Related]
8. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.
Baki E; Zwickel P; Zawierucha A; Ehehalt R; Gotthardt D; Stremmel W; Gauss A
World J Gastroenterol; 2015 Mar; 21(11):3282-90. PubMed ID: 25805935
[TBL] [Abstract][Full Text] [Related]
9. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants.
Reinisch W; Sandborn WJ; Panaccione R; Huang B; Pollack PF; Lazar A; Thakkar RB
Inflamm Bowel Dis; 2013 Jul; 19(8):1700-9. PubMed ID: 23665965
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study.
Christensen KR; Steenholdt C; Brynskov J
Scand J Gastroenterol; 2015 Aug; 50(8):1018-24. PubMed ID: 25861832
[TBL] [Abstract][Full Text] [Related]
11. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome.
García-Bosch O; Gisbert JP; Cañas-Ventura A; Merino O; Cabriada JL; García-Sánchez V; Gutiérrez A; Nos P; Peñalva M; Hinojosa J; García-Planella E; Muñoz F; Calvet X; Panés J
J Crohns Colitis; 2013 Oct; 7(9):717-22. PubMed ID: 23142005
[TBL] [Abstract][Full Text] [Related]
12. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.
Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P
Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209
[TBL] [Abstract][Full Text] [Related]
13. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis.
Feagan BG; Sandborn WJ; Lazar A; Thakkar RB; Huang B; Reilly N; Chen N; Yang M; Skup M; Mulani P; Chao J
Gastroenterology; 2014 Jan; 146(1):110-118.e3. PubMed ID: 24067881
[TBL] [Abstract][Full Text] [Related]
15. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2.
Sandborn WJ; Colombel JF; D'Haens G; Van Assche G; Wolf D; Kron M; Lazar A; Robinson AM; Yang M; Chao JD; Thakkar R
Aliment Pharmacol Ther; 2013 Jan; 37(2):204-13. PubMed ID: 23173821
[TBL] [Abstract][Full Text] [Related]
16. Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis.
Hussey M; Mc Garrigle R; Kennedy U; Holleran G; Kevans D; Ryan B; Breslin N; Mahmud N; McNamara D
Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):217-21. PubMed ID: 26587866
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab treatment of anti-TNF-naïve patients with ulcerative colitis: Deep remission and response factors.
Muñoz-Villafranca C; Ortiz de Zarate J; Arreba P; Higuera R; Gómez L; Ibáñez S; Merino O; Muñagorri A; Ogueta M; Rodriguez C; Nantes O; Ramirez de la Piscina P; Rodríguez I; Bernal A; Arévalo J; Cabriada J
Dig Liver Dis; 2018 Aug; 50(8):812-819. PubMed ID: 29625907
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis.
Fernández-Blanco JI; Fernández-Díaz G; Cara C; Vera MI; Olivares D; Taxonera C
Dig Dis Sci; 2018 Mar; 63(3):731-737. PubMed ID: 29372480
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.
Iborra M; Pérez-Gisbert J; Bosca-Watts MM; López-García A; García-Sánchez V; López-Sanromán A; Hinojosa E; Márquez L; García-López S; Chaparro M; Aceituno M; Calafat M; Guardiola J; Belloc B; Ber Y; Bujanda L; Beltrán B; Rodríguez-Gutiérrez C; Barrio J; Cabriada JL; Rivero M; Camargo R; van Domselaar M; Villoria A; Schuterman HS; Hervás D; Nos P;
J Gastroenterol; 2017 Jul; 52(7):788-799. PubMed ID: 27722996
[TBL] [Abstract][Full Text] [Related]
20. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
